New Hearing Medicine Syndicate Launched
10 January 2020
Collaborative syndicate launched to help bring hearing loss and tinnitus research groups closer together and support future therapies.
A new Hearing Medicines Discovery Syndicate has been established that aims to support the development of hearing therapeutics. The syndicate includes our very own NIHR Deafness and Hearing Problems BRC group, Action on Hearing Loss the UK Deafness/Hearing BRCs and the Cell and Gene Therapy Catapult.
Through the syndicate groups will be able to forge links with 'experts in hearing research, clinical trail design and cell and gene therapies as well as with specialist CROs and CMOs' as well as access licensing and other partnership opportunities.
Commenting on the new initiative Prof Anne Schilder the EI's NIHR Research Director said "We look forward to working with the Syndicate. There is a huge unmet need for new hearing therapeutics and recent scientific developments mean that there is now real potential for effective treatments to be developed and licensed for patients.”